|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Pipeline Insight: Multiple Sclerosis - The oral revolution
Analysis of disease-modifying drugs in late-stage clinical development for use in multiple sclerosis, including important clinical trial results, patient potential, market potential, and forecasts to 2016; supported by key opinion leader comments.
Pipeline Insight: Cancer Overview Lung Brain Head and Neck...
Overview of the late-phase pipeline for NSCLC, SCLC, mesothelioma, brain, head and neck, and thyroid cancer; analysis of key products, clinical trial data, sales forecasts to 2017, Datamonitor drug assessment summaries and opinion leader insights.
Pipeline Insight: Cancer Overview - Increasing diversity
Overview of the current solid cancer pipeline, including in-depth analysis of late-phase products for 17 tumor types, clinical trial data, sales forecasts through to 2016, Datamonitor drug assessment summaries and key opinion leader insight.
Pipeline Insight: Dyslipidemia
In-depth review of developmental drugs for the dyslipidemia market. Explores the commercial prospects of new agents against existing products, profiles unmet needs, and provides sales forecasts for the developmental agents to 2016.
Pipeline Insight: Breast Cancer 2008
Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large pat
Pipeline Insight: Depression
Analysis of drugs in late-stage clinical development for use in depression, including important clinical trial results, patient potential, market potential, and forecasts; supported by key opinion leader comments.
Pipeline Insight: Antithrombotics
In-depth analysis of products currently in development for the treatment of thrombosis and related cardiovascular diseases. It includes an up-to-date assessment of the structure of the pipeline, and key companies and research collaborations involved.<
Pipeline Insight: Non-insulin antidiabetics 2008
Iincretin mimetics is to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.
Pipeline Insight: Orphan Diseases in CNS - Part II
The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis’s Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of
Pipeline/Commercial Insight: Supportive Care in Oncology
Analysis of the current and future potential of the oncology supportive care market. Includes in-depth profiles of the late-phase pipeline, strategic recommendations and forecasts to 2016 for key marketed products across the seven major markets.
Pipeline Insight: Neuropathic Pain - Emerging drugs fail...
Analysis of drugs in late-stage clinical development for use in neuropathic pain, including important clinical trial results, patient potential, market potential, and indication-specific forecasts; supported by key opinion leader comments.
Pipeline Insight: Orphan Diseases in CNS
Analysis of the future Huntington’s disease market with revenue forecasts of key late-stage pipeline drugs and epidemiological scenario based forecasts to 2016. Conclusions are supported by key opinion leader and industry executive comments.
Pipeline Insight: Hematological Malignancies 2007
Overview of the products under clinical development for hematological malignancies. This includes an in-depth review and analysis of the late-phase candidates, sales forecasts to 2016, drug assessments and key opinion leader insights.
Pipeline Insight: Acute Stroke
In-depth review of developmental drugs for the acute stroke market. Explores the commercial prospects of new agents against existing products and profiles unmet market needs as well as unmet clinical needs, and provides sales forecasts to 2017.
Pipeline Insight: Substance Dependence - Part II: Alcohol
The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market req
Pipeline Insight: Upper GI Disorders - Generics will limit...
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remain
Pipeline Insight: Molecular Targeted Cancer Therapies
Overview of the pipeline molecular targeted cancer therapies (MTTs). This includes an in-depth review and analysis of the late-phase candidates, their sales forecasts to 2016, drug assessments, key opinion leader insights and pipeline dynamics.
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
Discussion of the market environment for nosocomial vaccines including epidemiology, costs and reimbursement structures and alternative prevention methods. Assessment of the pipeline and sizing estimates of patient potential for vaccines by pathogen.<
Pipeline Insight: Osteoporosis
Analysis of disease-modifying drugs in late-stage clinical development for use in osteoporosis, including important clinical trial results, patient potential, market potential, and forecasts to 2016; supported by key opinion leader comments.
Pipeline Insight: Hepatitis C - Small Molecules, Big Revolution
Less than 50% of chronically infected hepatitis C patients do not benefit from the current standard of care, pegylated interferon plus ribavirin. In the short-term, the treatment landscape is likely to be enriched by interferon or ribavirin replacemen
Pipeline Insight: Chronic and Acute Heart Failure
There is a clear need for new treatments for heart failure, as mortality and morbidity rates, although improving, remain high. Heart failure already represents the leading cause of hospitalization for patients over the age of 65 in Western markets and
Pipeline Insight:Antithrombotics-Anticoagulants & Antiplatelets
Datamonitor estimates the total revenue generated from new antithrombotics in the seven major markets will reach approximately $10bn by 2015, with novel oral anticoagulants contributing over 70% to this volume. However, barriers to entry exist and dev
Pipeline Insight: Hematological malignancies 2005
Given an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche`s Rituxan, it is no surprise that targeted treatments and immunotherapy dominate the pipeline. Integrating thes
|
